Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tonlamarsen · 2 trials · 4 indications
* Change from baseline in plasma angiotensinogen (AGT) levels and systolic blood pressure * Variability in plasma AGT levels and systolic blood pressure
Percent change in plasma AGT levels from Baseline to Week 4
Percent Change from baseline (Week 0) in plasma angiotensinogen (AGT) levels to Week 20
Change from baseline (Week 0) in mean office seated systolic blood pressure to Week 20
| Arm | Type | Description |
|---|---|---|
| Tonlamarsen | EXPERIMENTAL | 3 doses active drug will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks) |
| Placebo | PLACEBO_COMPARATOR | 3 doses of placebo will be administered by subcutaneous (under the skin) injection (one dose every 4 weeks) |
| Name | Type | Description |
|---|---|---|
| Tonlamarsen | DRUG | Tonlamarsen will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study |
| Placebo | DRUG | Placebo will be administered subcutaneously (under the skin) every 4 weeks during the randomized part of the study |
Key Inclusion Criteria: * Age 18 or older, body weight ≥ 50 kg with BMI ≤45.0 kg/m2 * Ready for discharge or recently discharged from the hospital to home (within the past 7 days) during which evaluation and/or treatment of acute severe hypertension (documented SBP ≥ 180 mmHg and/or DBP ≥ 110 mmHg)...
Top 12 of 20 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AstraZeneca PLC | AZN | 5 | PHASE3 | Baxdrostat |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Orforglipron, Clazakizumab |
| Alnylam Pharmaceuticals, Inc | ALNY | 2 | PHASE3 | Zilebesiran, ALN-AGT01 RVR |
| Mineralys Therapeutics, Inc. | MLYS | 1 | PHASE3 | lorundrostat |
| United Therapeutics Corporation | UTHR | 1 | PHASE3 | Ralinepag |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE2 | QCZ484, HJB647 |
| Vanda Pharmaceuticals Inc. | VNDA | 1 | PHASE2 | iloperidone |
| Kardigan, Inc. | KARD | 1 | PHASE2 | Tonlamarsen |
| Retension Pharmaceuticals. Inc. | RTSN | 1 | PHASE2 | RTN-001 |
| Opus Genetics, Inc. | IRD | 1 | PHASE1 | OPGx-BEST1 |
| ADARx Pharmaceuticals, Inc. | ADRX | 1 | PHASE1 | ADX-850 |
| CRISPR Therapeutics AG | CRSP | 1 | PHASE1 | CTX340 |